EKF Diagnostics share price jumps as it upgrades forecasts again!

The EKF Diagnostics share price has taken off again in midweek trading! Here are the key points of this UK healthcare share’s latest market update.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image of person checking their shares portfolio on mobile phone and computer

Image source: Getty Images.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The EKF Diagnostics (LSE: EKF) share price has been a bright spot in an otherwise gloomy market on Wednesday. Broader UK share prices continue to struggle as fears over rocketing inflation fray investor nerves. But EKF has posted strong double-digit gains after the release of fresh trading numbers.

At 74.8p per share, the EKF Diagnostics is currently 10% up from Tuesday’s close. The medical diagnostics giant touched three-week highs of 75.8p earlier in mid-week business.

A strong start to 2021

The EKF Diagnostics share price has risen 50% over the past year as demand for its medical kits has exploded during the pandemic. Indeed, the AIM-quoted company reported record sales and profit in 2020.

Pleasingly, EKF declared today that “this strong performance continues into the new financial year”. It has seen “a very meaningful recovery” in its core business, despite ongoing challenges created by Covid-19. In fact, EKF said it had “performed more strongly than expected”. That  included growth in the first quarter of 2021.

Furthermore, EKF said that it had “continued strong demand for our contract manufacturing services for Covid-19 sample collection devices and associated kits”.

EKF Diagnostics upgrades forecasts again!

Thanks to its strong trading in the year to date, EKF Diagnostics now expects to beat its recently upgraded full-year forecasts.

The business has a rich history of raising forecasts. And back in March it delivered another meaty upgrade to its full-year sales and profits expectations. This was prompted by the “significant expansion” of a multi-million dollar contract to supply Covid-19 sample collection kits to a global customer.

EKF said that March’s forecast bump was built “just on visible orders under the supply agreement and a continuing conservative approach to forecasting on the core business”. It said today, though, that continued strong trading during Q2 means that full-year trading should be “comfortably ahead” of that last upgrade.

Ambitious growth plans

EKF Diagnostics also painted a rosy picture for beyond the current period. It said that “there is clear scope to evolve our contract manufacturing activities beyond the current pandemic catalyst and to capture the significant additional potential for the core business”.

EKF unveiled steps which it believes will deliver “significant double-digit growth” in adjusted earnings during the next few years. These include investing in the core business to drive “aggressive” organic growth and targeting earnings-enhancing acquisitions. EKF said that it plans to spend between £10m and £15m to execute this strategy.

Finally, EKF announced that current chief executive Julian Baines will step down from the role to become non-executive deputy chair. He will be replaced by head of the company’s US operations, Mike Salter.

Today City analysts think annual earnings at EKF will rise 6% in 2021. This leaves the UK healthcare share trading on a forward price-to-earnings (P/E) ratio of 29 times.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

B&M shares are at record lows! Is now the time to consider buying?

The retailer, demoted from the FTSE 100 to the FTSE 250 last year, continues to struggle. But are B&M shares…

Read more »

Investing For Beginners

2 reasons why the stock market could hit 10,000 points by December

Jon Smith explains how the makeup of the UK stock market and the current valuation could support a move towards…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Why this FTSE 100 rocket is this investment trust’s number 1 holding

A UK investment trust is certainly going against the grain by having this FTSE 100 share as a high-conviction holding…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

These 2 FTSE growth stocks jumped 8% and 4.5% today!

Ben McPoland takes a closer look at a pair of FTSE stocks that are performing really well recently. Why are…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

This under‑the‑radar FTSE 100 growth stock is also a secret dividend superstar!

Harvey Jones belatedly wakes up to a brilliant FTSE 100 growth stock that has an equally remarkable track record of…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Barratt Redrow share price plunges 9% on profits hit – time to consider buying?

Harvey Jones says FTSE 100 housebuilders continue to suffer with the Barratt Redrow share price slumping on a profit warning.…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Growth Shares

Why the next month could make or break the Lloyds share price

Jon Smith outlines two key events in coming weeks that could influence the Lloyds share price, leading him to make…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

The B&M share price falls 13% despite improved Q1 sales. What should investors do?

Despite sales growing on a like-for-like basis, the B&M share price is falling yet again. So is the FTSE 250…

Read more »